IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy
BioSpace
Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a "best-in-class efficacy profile" for the PKC i
pharminent
April 13, 2026 (Last updated: April 13, 2026)
BioSpace
Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC i
